Breakthrough in Alzheimer's Treatment: Lilly's New Dosing Strategy Reduces Brain Swelling Risks

In a significant development for Alzheimer's disease treatment, Eli Lilly and Company has unveiled promising results from a recent study that indicates a modification in dosing could reduce the risk of brain swelling associated with its Alzheimer’s therapy, donanemab. This news marks a crucial advancement in managing the side effects often associated with Alzheimer's medications, offering hope to patients and healthcare providers alike.

Continue reading